dc.contributor.author | Lau, DK | |
dc.contributor.author | Aresu, M | |
dc.contributor.author | Planche, T | |
dc.contributor.author | Tran, A | |
dc.contributor.author | Lazaro-Alcausi, R | |
dc.contributor.author | Duncan, J | |
dc.contributor.author | Kidd, S | |
dc.contributor.author | Cromarty, S | |
dc.contributor.author | Begum, R | |
dc.contributor.author | Rana, I | |
dc.contributor.author | Li, S | |
dc.contributor.author | Mohamed, AA | |
dc.contributor.author | Monahan, I | |
dc.contributor.author | Clark, DJ | |
dc.contributor.author | Eckersley, N | |
dc.contributor.author | Staines, HM | |
dc.contributor.author | Groppelli, E | |
dc.contributor.author | Krishna, S | |
dc.contributor.author | Mayora-Neto, M | |
dc.contributor.author | Temperton, N | |
dc.contributor.author | Fribbens, C | |
dc.contributor.author | Watkins, D | |
dc.contributor.author | Starling, N | |
dc.contributor.author | Chau, I | |
dc.contributor.author | Cunningham, D | |
dc.contributor.author | Rao, S | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2023-01-13T15:31:42Z | |
dc.date.available | 2023-01-13T15:31:42Z | |
dc.date.issued | 2022-11-07 | |
dc.identifier | 6808328 | |
dc.identifier.citation | The Oncologist, 2022, pp. oyac230 - | en_US |
dc.identifier.issn | 1083-7159 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5653 | |
dc.identifier.eissn | 1549-490X | |
dc.identifier.eissn | 1549-490X | |
dc.identifier.doi | 10.1093/oncolo/oyac230 | |
dc.description.abstract | INTRODUCTION: Patients with gastrointestinal (GI) cancers have an increased risk of serious complications and death from SARS-CoV-2 infection. The immunogenicity of vaccines in patients with GI cancers receiving anti-cancer therapies is unclear. We conducted a prospective study to evaluate the prevalence of neutralizing antibodies in a cohort of GI cancer patients receiving chemotherapy following SARS-CoV-2 vaccination. MATERIALS AND METHODS: Between September 2020 and April 2021, patients with cancer undergoing chemotherapy were enrolled. At baseline (day 0), days 28, 56, and 84, we assessed serum antibodies to SARS-CoV-2 spike (anti-S) and anti-nucleocapsid (anti-NP) and concomitantly assessed virus neutralization using a pseudovirus neutralization assay. Patients received either the Pfizer/BioNTech BNT162b2, or the Oxford/AstraZeneca ChAdOx1 vaccine. RESULTS: All 152 patients enrolled had a prior diagnosis of cancer; colorectal (n = 80, 52.6%), oesophagogastric (n = 38, 25.0%), and hepato pancreatic biliary (n = 22, 12.5%). Nearly all were receiving systemic anti-cancer therapy (99.3%). Of the 51 patients who did not receive a vaccination prior to, or during the study, 5 patients had detectable anti-NP antibodies. Ninety-nine patients received at least one dose of vaccine prior to, or during the study. Within 19 days following the first dose of vaccine, 30.0% had anti-S detected in serum which increased to 70.2% at days 20-39. In the 19 days following a second dose, anti-S positivity was 84.2% (32/38). However, pseudovirus neutralization titers (pVNT80) decreased from days 20 to 39. CONCLUSION: Despite the immunosuppressive effects of chemotherapy, 2 doses of SARS-CoV-2 vaccines are able to elicit a protective immune response in patients' ongoing treatment for gastrointestinal cancers. Decreases in pseudoviral neutralization were observed after 20-39 days, re-affirming the current recommendation for vaccine booster doses. CLINICAL TRIAL REGISTRATION NUMBER: NCT04427280. | |
dc.format | Print-Electronic | |
dc.format.extent | oyac230 - | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | OXFORD UNIV PRESS | en_US |
dc.relation.ispartof | The Oncologist | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | COVID-19 | |
dc.subject | SARS-CoV-2 | |
dc.subject | anti-spike | |
dc.subject | chemotherapy | |
dc.subject | gastrointestinal cancer | |
dc.subject | immunity | |
dc.subject | pseudovirus | |
dc.subject | vaccines | |
dc.title | SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-09-29 | |
dc.date.updated | 2023-01-13T15:30:57Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1093/oncolo/oyac230 | en_US |
rioxxterms.licenseref.startdate | 2022-11-07 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/36342104 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials/Gastrointestinal Cancers Clinical Trials (hon.) | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1093/oncolo/oyac230 | |
icr.researchteam | Medicine (RMH) | en_US |
dc.contributor.icrauthor | Starling, Naureen | |
dc.contributor.icrauthor | Chau, Ian | |
dc.contributor.icrauthor | Cunningham, David | |
icr.provenance | Deposited by Mr Arek Surman on 2023-01-13. Deposit type is initial. No. of files: 1. Files: oyac230.pdf | |